8-K: Curaleaf Rebuts Aurora's Claims, Highlights Offer Premium

Curaleaf Holdings, Inc. issued a press release responding to Aurora Cannabis Inc.'s Directors' Circular, reaffirming its offer and criticizing Aurora's financial performance and management decisions.

Summary

• Curaleaf Holdings, Inc. is responding to Aurora Cannabis Inc.'s recent circular, asserting that its offer provides a 45% premium and significant future upside for Aurora shareholders.
• Curaleaf criticizes Aurora's financial management, pointing to substantial shareholder dilution through equity issuances totaling $398 million since September 2020 and ongoing dilution from its ATM program.
• The company highlights that Aurora's Board has sold shares at prices significantly below the current offer, contradicting their valuation arguments.
• Curaleaf states that Aurora's own guidance indicates a declining business, with fiscal 2027 revenue projected to return to fiscal 2025 levels and adjusted EBITDA expected to decrease.
• Aurora's operating cash flow was negative in the June quarter, and Curaleaf contrasts this with its own generation of $157 million in operating cash flow over the last twelve months.
• Curaleaf argues that Aurora's continuous 'transformations' over six years, with associated costs charged for seven consecutive years, indicate a flawed business model rather than a temporary phase.
• The company emphasizes its own superior fundamentals, including positive operating cash flow, a strong position to benefit from industry and regulatory catalysts, and access to institutional debt markets.
• Curaleaf's offer provides Aurora shareholders with equity in a larger, more diversified cannabis company with positive cash flow, international opportunities, and regulatory catalysts.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the aggressive and critical tone used by Curaleaf in response to Aurora's circular, highlighting significant financial and operational concerns within Aurora, which suggests a potentially unfavorable acquisition target or a contentious deal.

Positives

• Curaleaf's offer represents a 45% premium to Aurora's unaffected trading price, with an 110% premium excluding cash.
• The offer implies a CY2026E Adjusted EBITDA multiple of 12.0x for Aurora, which is over 68% higher than comparable Canadian peers.
• Curaleaf generated $157 million of operating cash flow in the LTM period, contrasting with Aurora's negative operating cash flow in the June quarter.
• Curaleaf generated $50 million in operating cash flow and $17 million in free cash flow in the first half of 2026, while investing $33 million in growth.
• Curaleaf successfully raised $500 million in senior secured notes, indicating lender confidence.
• Curaleaf's UTP balance as a percentage of TEV (13%) is lower than the U.S. cannabis peer average of approximately 30%.
• Curaleaf generated $145 million of operating cash flow over the LTM period ended June 30, 2026, with projected growth to $165 million by FY27E.
• Curaleaf's net debt represents approximately 25% of its total capitalization, below the peer average of 37%.

Negatives

• Aurora has experienced massive shareholder dilution, raising $398 million through equity issuances since September 2020, with continued dilution through its ATM program.
• Aurora's Board sold shares through its ATM program at average prices of $3.57 and $3.09 per share, materially below the price it now argues is inadequate.
• Aurora's own guidance forecasts fiscal 2027 revenue to return to fiscal 2025 levels, with adjusted EBITDA expected to decline.
• Aurora's operating cash flow was negative in the June quarter.
• Aurora has incurred cumulative operating cash flow losses of over C$480 million in the last six years.
• Aurora has recorded over C$400 million in inventory impairments and business transformation costs.
• Aurora's share price has declined 97% over the past six years, significantly underperforming peers.
• Aurora's CEO runs the business from the U.S. while the company is based in Canada.

Risks

• Aurora's management's own guidance points to declining revenue and EBITDA, continued cash burn, and further shareholder dilution.
• Aurora's business model appears to be a continuous transformation, with transformation costs charged for seven consecutive years.
• Auditors have reported ineffective controls over inventory and biological assets in Aurora's filings since FY2020, and KPMG resigned as Aurora's auditor in April 2024.
• Canadian medical revenue for Aurora has declined significantly due to reduced reimbursement rates by Veterans Affairs Canada.
• German regulators have removed insurance reimbursement for Aurora's German business.
• Aurora's share price has hit all-time lows under the current management team.
• The proposed transaction structure encourages Aurora shareholders to complete a transaction as soon as possible to lock in the exchange ratio and participate in potential upside with Curaleaf, implying a risk of not doing so.
• Curaleaf's uncertain tax position (UTP) related to IRC section 280E is a well-understood phenomenon in the U.S. cannabis market, though the rescheduling of medical cannabis has ceased future accruals of this liability.

Future Outlook

Curaleaf's offer provides Aurora shareholders with the opportunity to participate in the upside of a larger, more diversified cannabis platform with positive cash flow generation, international expansion opportunities, and multiple regulatory catalysts. Curaleaf projects its operating cash flow to grow to approximately $165 million by FY27E, a significant increase over FY25 levels.

Management Comments

• "Aurora's continued refusal to engage in a meaningful price discussion regarding this transaction is disappointing and shows disregard for the interests of the Company's own shareholders. Not once has there been a counteroffer presented to us, which shows managements' motives to preserve their own positions versus creating value for shareholders," said Boris Jordan, Chairman and Chief Executive Officer of Curaleaf.
• "Rather than working constructively to evaluate a proposal that delivers immediate value and a substantial premium, Aurora's Board has chosen to rely on hollow arguments that are contradicted by its own actions."
• "Aurora's response sidesteps the fundamental question facing shareholders: if management's plan creates greater value than our offer, where is the evidence? Aurora's own guidance points to declining revenue and EBITDA, continued cash burn and further shareholder dilution. By contrast, Curaleaf offers shareholders a 45% premium and immediate exposure to one of the largest and most diversified cannabis companies in the world."
• "We remain ready and willing to engage constructively with Aurora to discuss this offer at any point."
• "If their current iteration of the business plan and transformation is going to work, why does management's own forecast anticipate lower revenue and lower EBITDA next year?"
• "If Aurora is truly committed to maximizing value for shareholders, why have they refused to engage in a single constructive conversation regarding this shareholder maximizing transaction?"

Industry Context

StockSavvy.ai notes that this exchange highlights the ongoing consolidation and strategic maneuvering within the cannabis industry, where companies are vying for market share and shareholder value amidst evolving regulatory landscapes. Curaleaf's aggressive stance and detailed financial comparisons suggest a belief that Aurora's current standalone strategy is unsustainable, positioning Curaleaf as a more stable and growth-oriented alternative.

Comparison to Industry Standards

• Curaleaf's offer premium of 45% to Aurora's unaffected trading price is noted to be in the 63rd percentile of Canadian M&A premiums paid over the last 10 years.
• The implied CY2026E Adjusted EBITDA multiple of 12.0x for Aurora under Curaleaf's offer is stated to be more than 68% higher than comparable Canadian peers.
• Curaleaf's UTP balance as a percentage of TEV (13%) is presented as one of the lowest relative to the U.S. cannabis peer average of approximately 30%.
• Curaleaf's net debt to LTM adjusted EBITDA ratio is projected to de-lever from approximately 3.3x to 2.7x by FY2027E, which is a faster de-leveraging than the peer average of approximately 3% growth in operating cash flow.
• Multi-Class Issuers on the TSX have historically outperformed the broader S&P / TSX Composite index with returns of 295% versus 152% for the index.
• Curaleaf's relative share price performance has exceeded U.S. cannabis peers by approximately 42 percentage points and Aurora by approximately 57 percentage points since August 16, 2024.

Corporate Governance

Legal Proceedings

• Auditors have reported ineffective controls over inventory and biological assets in Aurora's filings since FY2020.

Stakeholder Impact

• Shareholders: Curaleaf's offer provides a 45% premium and potential future upside, contrasting with Aurora's history of dilution and declining performance.
• Shareholders: Aurora's continued equity issuances and cash burn pose risks to shareholder value.
• Shareholders: The offer encourages Aurora shareholders to complete a transaction promptly to lock in the exchange ratio and participate in potential upside.

Next Steps

• Aurora shareholders are urged to read the offer documents carefully and in their entirety.
• Offer documents are available on Curaleaf's website, SEDAR+, and EDGAR.
• Shareholders are encouraged to visit these sites for additional information regarding the offer, strategic rationale, expected benefits, FAQs, and other relevant materials.

Key Dates

Recommendation

While Curaleaf presents a strong case against Aurora's current management and financial trajectory, highlighting significant premiums and its own superior fundamentals, the offer is still subject to negotiation and Aurora's response. The aggressive tone and focus on Aurora's weaknesses suggest a potential for a contentious deal. For Aurora shareholders, holding allows for further evaluation of Curaleaf's offer and potential counter-offers or negotiations, while for Curaleaf investors, the current situation reflects a strategic move that warrants monitoring rather than immediate action.

Keywords

cannabis, acquisition, merger, Aurora Cannabis, Curaleaf Holdings, shareholder value, dilution, financial performance